Oncotelic Therapeutics, Inc. (OTLC) Form 8-K — Jun 29, 2026
$OTLCForm 8-KItems 1.01, 2.03, 3.02, 9.01Filed Jun 29, 2026, 8:00 AM ET0001493152-26-031124Original filing
Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, issuing a convertible promissory note with a gross principal amount of $178,410. The note carries a 12% original issue discount and a 12% annual interest rate, maturing one year from the June 23, 2026 issue date. As part of the transaction, the company issued 500,000 shares of common stock as commitment shares to the investor.
Key figures
- Debt Amount
- 178410
- Interest Rate
- 12%
- Purchase Price
- 157,000.80
- Conversion Price
- $0.06 fixed or 85% of lowest VWAP
- Commitment Shares
- 500000
- Shares Outstanding
- 443,615,716
- Original Issue Discount
- 21,409.20
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.